Cover 2: Editorial Board
(Source: Experimental Hematology)
Source: Experimental Hematology - January 1, 2023 Category: Hematology Source Type: research
miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells
Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative neoplasm characterized by the uncontrolled proliferation of myeloid cells. Primarily, BCR-ABL1 acts as a constitutively active tyrosine kinase that alters cell proliferation, differentiation, survival, and genetic stability in hematopoietic cells in which it is expressed [1,2]. (Source: Experimental Hematology)
Source: Experimental Hematology - December 16, 2022 Category: Hematology Authors: Yutthana Rittavee, J érôme Artus, Christophe Desterke, Isidora Simanic, Lucas Eduardo Botelho de Souza, Sandra Riccaldi, Sabrina Coignard, Yousef Ijjeh, Patricia Hugues, Annelise Bennaceur-Griscelli, Ali G. Turhan, Adlen Foudi Tags: Article Source Type: research
miR-495-3p Sensitizes BCR-ABL1 Expressing Leukemic cells to Tyrosine Kinase Inhibitors by Targeting Multidrug Resistance 1 Gene including in T315I Mutated cells
Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative neoplasm characterized by the uncontrolled proliferation of myeloid cells. Primarily, BCR-ABL1 acts as a constitutively active tyrosine kinase that alters cell proliferation, differentiation, survival, and genetic stability in hematopoietic cells in which it is expressed [1,2]. (Source: Experimental Hematology)
Source: Experimental Hematology - December 16, 2022 Category: Hematology Authors: Yutthana Rittavee, J érôme Artus, Christophe Desterke, Isidora Simanic, Lucas Eduardo Botelho de Souza, Sandra Riccaldi, Sabrina Coignard, Yousef Ijjeh, Patricia Hugues, Annelise Bennaceur-Griscelli, Ali G. Turhan, Adlen Foudi Source Type: research
Fetal allotransplant recipients are resistant to graft-versus-host disease
In utero hematopoietic cell transplantation (IUHCT) is an experimental treatment for inherited immune, metabolic, and hematologic disorders with potential advantages over postnatal hematopoietic cell transplantation (HSCT). In preclinical studies, IUHCT achieves long-term alloengraftment without myeloablation, immunosuppression, or the need for an HLA-matched donor1 –3. Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality after postnatal HSCT4–7 and is the one of the greatest theoretical risks of IUHCT8. (Source: Experimental Hematology)
Source: Experimental Hematology - December 16, 2022 Category: Hematology Authors: John S. Riley, Lauren E. McClain, John D. Stratigis, Barbara E. Coons, Sourav K. Bose, Apeksha Dave, Brandon M. White, Haiying Li, Stavros P. Loukogeorgakis, Camila G. Fachin, Andre I.B.S. Dias, Alan W. Flake, William H. Peranteau Source Type: research
The (intra-aortic) hematopoietic cluster cocktail: what is in the mix?
Understanding de novo hematopoietic cell generation, i.e. transition or differentiation of a non-hematopoietic precursor to a hematopoietic cell identity, has long been a goal in the field of developmental hematopoiesis. Over a century ago, before functional assays existed, histological studies on many species of early-stage vertebrate embryos (Figure 1A) revealed the existence of clusters of hematopoietic-like cells tightly associated to the ventral aortic endothelium, frequently near the divergence of vascular branches (Figure 1B) (Dantschakoff, 1907; Emmel, 1916; Jordan, 1916; Jordan, 1917; Maximow, 1909; Minot et al., ...
Source: Experimental Hematology - December 15, 2022 Category: Hematology Authors: Chris S. Vink, Elaine Dzierzak Tags: Review Source Type: research
Assessing the frequency of CD163+ tumor-associated macrophages and CD3+ T lymphocytes between MGUS and plasma cell myeloma
Plasma cell dyscrasias (PCDs) are a heterogeneous group of diseases characterized by the expansion of monoclonal bone marrow (BM) plasma cells [1]. The most common is monoclonal gammopathy of undetermined significance (MGUS), which is a premalignant PCD that consistently precedes multiple myeloma (MM), with a 1% risk of progression per year [2,3]. MGUS is found in 3.2% of individuals aged ≥50 years and 5.3% of those aged ≥70 years, increasing to 8.9% of men aged ≥85 years [4,5]. Because MGUS is more prevalent as we age, it follows that the incidence of MM is also strongly associated with age. (Source: Experimental Hematology)
Source: Experimental Hematology - December 10, 2022 Category: Hematology Authors: Aaron Niblock, Simon Rajendran, Charles Laverty, Philip Logue, H. Denis Alexander Tags: Brief Communication Source Type: research
Assessment of the frequency of CD163+ tumor-associated macrophages between MGUS and plasma cell myeloma
Plasma cell dyscrasias (PCDs) are a heterogeneous group of diseases characterized by the expansion of monoclonal bone marrow (BM) plasma cells [1]. The most common is monoclonal gammopathy of undetermined significance (MGUS), which is a premalignant PCD that consistently precedes multiple myeloma (MM), with a risk of progression of 1% per year [2,3]. MGUS is found in 3.2% of individuals aged ≥50 years and 5.3% of those aged ≥70 years, increasing to 8.9% of men aged ≥85 years [4,5]. Because MGUS is more prevalent as we age, it makes sense that the incidence of MM is also strongly associated with age. (Source: Experimental Hematology)
Source: Experimental Hematology - December 10, 2022 Category: Hematology Authors: Aaron Niblock, Simon Rajendran, Charles Laverty, Philip Logue, Denis Alexander Tags: Brief Communication Source Type: research
Assessing the frequency of CD163 Tumour Associated Macrophages between MGUS and Plasma Cell Myeloma
Plasma cell dyscrasias (PCD) are a heterogeneous group of diseases characterised by the expansion of monoclonal bone marrow (BM) plasma cells. 1 The most common is Monoclonal Gammopathy of Undetermined Significance (MGUS) which is a premalignant PCD that consistently precedes multiple myeloma (MM) with a 1% risk of progression per year.2,3 (Source: Experimental Hematology)
Source: Experimental Hematology - December 10, 2022 Category: Hematology Authors: Aaron Niblock, Simon Rajendran, Charles Laverty, Philip Logue, Denis Alexander Tags: Brief Communication Source Type: research
Heme-dependent induction of mitophagy program during differentiation of murine erythroid cells
Heme is the principal component of hemoglobin that carries oxygen molecules that are abundantly produced during the maturation of erythroblasts into red blood cells (RBCs). Half of the steps of heme synthesis are catalyzed in mitochondria [1]. In contrast to this dependence on mitochondria for heme synthesis, erythroblasts undergo enucleation and clearance of cytoplasmic components, including mitochondria, which are potential consumers of oxygen and can generate deleterious reactive oxygen species (ROS). (Source: Experimental Hematology)
Source: Experimental Hematology - December 5, 2022 Category: Hematology Authors: Masatoshi Ikeda, Hiroki Kato, Hiroki Shima, Mitsuyo Matsumoto, Eijiro Furukawa, Yan Yan, Ruiqi Liao, Jian Xu, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Emery H. Bresnick, Kazuhiko Igarashi Tags: Article Source Type: research
Heme-dependent induction of mitophagy program during murine erythroid cell differentiation
Heme is the principal component in hemoglobin to carry oxygen molecules that are abundantly produced during the maturation of erythroblasts into red blood cells (RBCs). Half of the steps of heme synthesis are catalyzed in mitochondria 1. In contrast to this dependence on mitochondria for heme synthesis, erythroblasts undergo enucleation and clearance of cytoplasmic components including mitochondria, which are potential oxygen consumers and can generate deleterious reactive oxygen species (ROS). The fidelity of this process is crucial to produce red blood cells with the capacity to transfer oxygen and confer organismal surv...
Source: Experimental Hematology - December 5, 2022 Category: Hematology Authors: Masatoshi Ikeda, Hiroki Kato, Hiroki Shima, Mitsuyo Matsumoto, Eijiro Furukawa, Yan Yan, Ruiqi Liao, Jian Xu, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Emery H. Bresnick, Kazuhiko Igarashi Tags: Article Source Type: research
Cover 2: Editorial Board
(Source: Experimental Hematology)
Source: Experimental Hematology - December 1, 2022 Category: Hematology Source Type: research
Reduced IFN- γ levels along with changes in hematologic and immunologic parameters are key to COVID-19 severity in Bangladeshi patients
The coronavirus disease 2019 (COVID-19) pandemic, engendered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a global disaster since its outbreak in Wuhan, China, in December 2019 [1]. As of March 2022, there were over 507 million confirmed COVID-19 cases and a death toll of more than 62 million, with the case fatality rate ranging from 0.04% to 18.18% reported worldwide; however, Bangladesh experienced approximately 2 million cases and total deaths of less than 30,000 [2]. (Source: Experimental Hematology)
Source: Experimental Hematology - November 26, 2022 Category: Hematology Authors: Mohammed Moinul Islam, Shafiqul Islam, Ridwan Ahmed, Mohit Majumder, Bishu Sarkar, Md. Ejajur Rahman Himu, Md Kawser, Alamgir Hossain, Mohammad Jewel Mia, Rashed Rezwan Parag, Md. Rakibul Hassan Bulbul, Shakeel Ahmed, M.A. Sattar, Rajdeep Biswas, Moumita Tags: Research Article Source Type: research
Reduced IFN- γ along with Changes in Hematological and Immunological parameters are Key to COVID-19 Severity in Bangladeshi Patients
The COVID-19 pandemic engendered by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has had a global disaster since its outbreak in Wuhan, China in December 2019 [1]. As of March 2022, there were over 507 million confirmed COVID-19 cases and a death toll of more than 62 million with a case-fatality rate ranging from 0 ∙04%-18∙18% reported worldwide whereas Bangladesh has experienced approximately 2 million cases and total death of less than 30000 [2]. The disparity of the mortality rates caused by COVID-19 in different regions of the world has been a puzzling conundrum but grossly alluded to demographic va...
Source: Experimental Hematology - November 26, 2022 Category: Hematology Authors: Mohammed Moinul Islam, Shafiqul Islam, Ridwan Ahmed, Mohit Majumder, Bishu Sarkar, Md. Ejajur Rahman Himu, Md Kawser, Alamgir Hossain, Mohammad Jewel Mia, Rashed Rezwan Parag, Md. Rakibul Hassan Bulbul, Shakeel Ahmed, M.A. Sattar, Rajdeep Biswas, Moumita Tags: Article Source Type: research
Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms
BCR-ABL-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are characterized by the expansion of at least one myeloid lineage cells caused by acquired somatic mutations [1]. A point mutation of valine to phenylalanine at position 617 (V617F) on Janus kinase 2 (JAK2) is the most common mutation found in MPNs [2-5]. JAK2 normally binds to the intracellular domain of cytokine receptors and transduces signals into cells in response to cytokines. (Source: Experimental Hematology)
Source: Experimental Hematology - November 25, 2022 Category: Hematology Authors: Chang Liu, Misa Imai, Yoko Edahiro, Shuichi Mano, Hiraku Takei, Mai Nudejima, Akira Kurose, Soji Morishita, Miki Ando, Satoshi Tsuneda, Marito Araki, Norio Komatsu Source Type: research
Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study
Aplastic anemia (AA) is a disease characterized by bone marrow hematopoietic failure. AA can be classified as inherited and acquired, and acquired AA can be further categorized into primary and secondary ones. Acquired primary AA includes severe AA (SAA) and non-SAA (NSAA) based on their peripheral blood cell count. In the past 30 years, immunosuppressive therapy (IST) containing antithymic globulin (ATG) and cyclosporin A has been used as the first-line drug therapy for SAA or transfusion-dependent NSAA not suitable for hematopoietic stem cell transplantation (HSCT) [1 –3]. (Source: Experimental Hematology)
Source: Experimental Hematology - November 15, 2022 Category: Hematology Authors: Yarong Chi, Qinglin Hu, Chen Yang, Miao Chen, Bing Han Tags: Article Source Type: research
